Formulation and Evaluation of Transdermal Patches for Chronic Pain Relief

The skin has been used to apply various therapeutic agents and cosmetic products for a long period of time, but only recently the skin is being used as a route for drug delivery systems. Almost two third of the drugs available in the market are taken orally but they pose several problems like gastric degradation, first pass metabolism and low bioavailability thus showing low efficacy. Transdermal drug delivery systems (TDDS) show enhanced features and delivery of drugs through the patient’s skin. TDDS show better therapeutic effects with minimum side effects and they are designed to release the drug at zero order rate following its application on the skin. Millions of people worldwide suffer from arthritis, burdening healthcare systems with symptoms such as joint pain, inflammation, and decreased mobility. The preferred drugs prescribed to these patients include Diclofenac or other Non-steroidal anti-inflammatory drugs (NSAIDS). However, chronic consumption of these drugs is associated with gastric irritation and renal toxicity. Thus, new and innovative approaches to treating localized pain and inflammation are critical, making transdermal medication delivery methods that incorporate safer painkillers the need of the hour.This work centers on formulating transdermal patches using Etodolac, a relatively safer NSAID, so that relief in pain and inflammation control is achieved with the added advantage of mitigating the gastrointestinal adverse effects commonly associated with oral drug administrationthus augmenting the safety and tolerability profile of NSAID therapy. The versatility of the patch extends its application to a variety of conditions, including different forms of arthritis, muscle pain, and more. Our study encompasses the formulation of the transdermal patch, involving a carefully crafted combination of polymers, permeation enhancers and drug reservoirs to optimize drug release kinetics and enhance skin permeation.